G/MA/QR/N/EU/5/Add.7  
 
7 October  2021 
(21-7623) Page: 1/4 
Committee on Market Access  Original: English  
 
  
NOTIFICATION PURSUANT TO THE DECISION ON NOTIFICATION  PROCEDURE S 
FOR QUANTITATIVE RESTRICTIONS (G/L/59/REV.1)  
EUROPEAN UNION 
Addendum  
The following communication, dated 7 October  2021, is being circulated at the request of the 
delegation of the European Union . 
 
A. Notifying Member : European Union  
B. Date of notification : 7 October  2021 
C. First time notification:  
 Yes 
 No, last notification was made in (doc. symbol ): G/MA/QR/N/EU/5, 
G/MA/QR/N/EU/5/Add.1 , G/MA/QR/N/EU/5/Add.2 , G/MA/QR/N/EU/5/Add.3 , 
G/MA/QR/N/EU/5/Add.4 , and G/MA/QR/N/EU/5/Add.5, and G/MA/QR/N/EU/5/Add. 6  
D. Type of notification:  
 1. Complete (i.e. notification of all quantitative restrictions in force ) 
 2. Changes to a notification previously made in G/MA/QR/N/EU/5/Add.6  which are of the 
following nature : 
  2.1 Introduction of new re strictions, as listed in Section 1. 
  2.2 Elimination of restrictions, as described in G below . 
  2.3 Modification of a previously notified restriction, as described in Section 1. 
 3. Reverse notification of restrictions maintain ed by (Member ):  
E. The notification provides information for the follo wing biennial period 
(e.g.  2012 -2014): 2020-2022 and relates to restrictions in force as of 07.10. 2021 
F. This notification contains information* relating to:  
 Section  1: List of quantitative restrictions that are currently in force . 
 Section  2: Cross -reference to other WT O notifications with information on quantitative 
restrictions that are currently in force and additional information . 
 The EU is notifying the extension of the export authorisation requirement for Covid -19 
vaccines, applicable to exports of vaccines produ ced by companies with which the EU has 
Advance Purchase Agreements (contained in notification G/MA/QR/N/EU/5/Add. 6) until 31 
December 2021. Based on the principle of international solidarity, exports to more than 100 
countries continue to be exempted from the measure, such as, in particular, exports related 
to COVAX and in the context of a humanitarian emergency response.  
 
* In English  only.  
  G/MA/QR/N/EU/5/Add.7  
 
- 2 - Section 1: List of quantitative restrictions that are currently in force  
 
QR 
No.  General 
description of 
the restriction  Type of 
restriction  Tariff line code  (s) 
affected, based on 
HS (2017)  Detailed Product 
Description  WTO Justification  
and Ground for 
Restriction, e.g. 
Other International 
Commitments  Nation al legal basis and 
entry into force  Administration, 
modification of 
previously notified 
measures, and other 
comments  
1 2 3 4 5 6 7 
1 Export 
authorisation for 
COVID -19 
vaccines  
 NAL-X ex 3002 20  
ex 2933 99  
ex 2934 99  
ex 3002 90  
ex 3504 00  Vaccines against SARS -
related coronaviruses 
(SARS -CoV species), 
irrespective of their 
packaging, and active 
substances including 
master and working cell 
banks used for the 
manufacture of such 
vaccines  Protection of human life 
or health, inter alia  
 
 Commiss ion Implementing 
Regulation (EU) 
2021/1728 (29 September 
2021)  
extending Implementing 
Regulation (EU) 2021/521 
making specific 
arrangements to the 
mechanism making the 
exportation of certain 
products subject to the 
production of an export 
authorisation;  
Official Journal L  
2021/1728, 29.09.2021  
 
https://eur -
lex.europa.eu/legal -
content/EN/TXT/?uri=CELE
X%3A32021R1728  
 
Application period: from 
1.10.2021 until 31.12.2021  Administration: 
Competent authorities in 
EU Member States  
 
Authorisations are 
granted to the extent that 
the volume of exports is 
such that it does not pose 
a threat to the execution 
of Advance Purchase 
Agreements that the 
European Union has 
concluded with vaccine 
manufacturers.  
 
Authorisations are 
granted where exports do 
not pose a threat to the 
security of supply within 
the European Union.  
 
In order to determine 
whether the condition 
above is fulfilled, the 
competent authorities 
shall assess t he following 
factors:  
 
       1) Does the destination 
country restrict its own 
exports of vaccines or 
their raw materials, 
either by law or other 
means?  
And  
  G/MA/QR/N/EU/5/Add.7  
 
- 3 - QR 
No.  General 
description of 
the restriction  Type of 
restriction  Tariff line code  (s) 
affected, based on 
HS (2017)  Detailed Product 
Description  WTO Justification  
and Ground for 
Restriction, e.g. 
Other International 
Commitments  Nation al legal basis and 
entry into force  Administration, 
modification of 
previously notified 
measures, and other 
comments  
1 2 3 4 5 6 7 
       2) Are the conditions 
prevailing in the 
destination country 
better or worse than the 
EU's, in particular its 
epidemiological situation, 
its vaccination rate and 
its access to vaccines?  
 
Exemptions include, inter 
alia: 
 
- exports in the context 
of humanitar ian aid;  
 
- exports to low and  
middle income countries 
in the COVAX Advance 
Market Commitment 
(AMC) list  
       (https://www.gavi.org/ne
ws/media -room/92 -low-
middle -income -
economies -eligible -
access -covid-19-
vaccines -gavi-covax -amc 
  
  G/MA/QR/N/EU/5/Add.7  
 
- 4 - QR 
No.  General 
description of 
the restriction  Type of 
restriction  Tariff line code  (s) 
affected, based on 
HS (2017)  Detailed Product 
Description  WTO Justification  
and Ground for 
Restriction, e.g. 
Other International 
Commitments  Nation al legal basis and 
entry into force  Administration, 
modification of 
previously notified 
measures, and other 
comments  
1 2 3 4 5 6 7 
       - exports of goods 
purchased and/or 
delivered through 
COVAX, UNICEF and 
PAHO with destination to 
any other COVAX 
participating country;  
 
- EU overseas countries 
and territories;  
 
- Andorra, the Faroe 
Islands, San Marino, 
Vatican City, Büsingen, 
Helgoland, Livigno, Ceuta 
and Melilla;  
 
- Iceland, Liechtenstein 
and Norway . 
 
__________